6 completed, 4 terminated, 3 unknown, 2 recruiting. 12 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Terminated 4, Completed 3, Recruiting 2, Unknown 2, Withdrawn 1 |
| Phase 1 | 9 | Completed 6, Recruiting 1, Suspended 1, Unknown 1 |
Follow vactosertib: new trials by email Literature Review of vactosertib trials Research Report on vactosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma Vactosertib, Standard of Care Preoperative Therapy - Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma | Phase 2 | Recruiting | Melissa Lumish | 25 | 2024-09-30 | 2026-10-05 |
| Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma Vactosertib - Osteosarcoma | Phase 1 / Phase 2 | Recruiting | MedPacto, Inc. | 78 | 2023-05-01 | 2026-10-07 |
| Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor Pembrolizumab, Vactosertib - Acral Melanoma, Mucosal Melanoma | Phase 2 | Terminated | Yonsei University | 14 | 2023-02-09 | 2025-04-02 |
| As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers Vactosertib - Gastric Cancer | Phase 2 | Unknown | Samsung Medical Center | 43 | 2022-10-01 | 2022-06-15 |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Vactosertib, Fludarabine Phosphate, Cyclophosphamide - Colorectal Cancer, Hematologic Malignancy | Phase 1 | Suspended | David Wald | 12 | 2022-09-09 | 2026-07-14 |
| Vactosertib and Durvalumab in Gastric Cancer durvalumab and vactosertib - Stomach Neoplasm | Phase 2 | Unknown | Hark Kyun Kim | 55 | 2021-06-01 | 2022-11-30 |
| Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF) Vactosertib, Imatinib - Dermoid | Phase 2 | Withdrawn | MedPacto, Inc. | 2021-06-01 | 2024-12-09 | |
| Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma. Vactosertib - Pancreas Cancer | Phase 1 | Unknown | Samsung Medical Center | 24 | 2021-04-19 | 2022-06-15 |
| Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects Vactosertib 300 mg BID and pembrolizumab 200 mg IV - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | MedPacto, Inc. | 11 | 2020-12-17 | 2024-12-09 |
| Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients Vactosertib - Myeloproliferative Neoplasm | Phase 2 | Terminated | Weill Medical College of Cornell University | 2 | 2019-11-22 | 2025-07-02 |
| Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases Hepatectomy, Pembrolizumab, Vactosertib - Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8 | Phase 2 | Terminated | Chloe Atreya, MD, PhD | 6 | 2019-07-22 | 2025-12-31 |
| A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor vactosertib/imatinib combination - Desmoid Tumor | Phase 1 / Phase 2 | Completed | Hyo Song Kim | 24 | 2019-04-15 | 2024-05-13 |
| Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer TEW-7197 - Metastatic Colorectal Cancer, Gastric Cancer | Phase 1 / Phase 2 | Completed | MedPacto, Inc. | 120 | 2018-12-20 | 2025-03-25 |
| TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer TEW-7197 - Metastatic Gastric Cancer | Phase 1 / Phase 2 | Completed | MedPacto, Inc. | 62 | 2018-08-15 | 2024-12-09 |
| Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects TEW-7197 - Healthy Volunteers | Phase 1 | Completed | MedPacto, Inc. | 16 | 2018-08-08 | 2020-04-14 |
| Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma Vactosertib, Pomalidomide - Multiple Myeloma | Phase 1 | Completed | Koen van Besien | 18 | 2017-07-21 | 2024-05-24 |
| First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors TEW-7197 - Advanced Stage Solid Tumors | Phase 1 | Completed | MedPacto, Inc. | 35 | 2014-07-29 | 2019-05-09 |
Stomach Neoplasms (5) · Colorectal Neoplasms (3) · Multiple Myeloma (2) · Neoplasm Metastasis (2) · Adenocarcinoma Of Esophagus (1) · Anemia (1) · Camurati-Engelmann Syndrome (1) · Carcinoma, Non-Small-Cell Lung (1) · Dermoid Cyst (1) · Desmoid Tumors (1) · Esophageal Neoplasms (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Keratoacanthoma familial (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
MedPacto, Inc. (7) · Samsung Medical Center (2) · Chloe Atreya, MD, PhD (1) · David Wald (1) · Hark Kyun Kim (1) · Hyo Song Kim (1) · Koen van Besien (1) · Melissa Lumish (1) · Weill Medical College of Cornell University (1) · Yonsei University (1)
South Korea (10) · United States (7)
Sunjin Hwang, MD (3) · Minkyu Heo (2) · Benjamin Tomlinson, MD (1) · Chloe Atreya, MD, Ph.D. (1) · Ilho Ha, PhD (1) · Joseph M Scandura, MD, PhD (1) · Koen van Besien, MD, PhD (1) · Melissa Lumish, MD (1) · Minkyu Jung (1) · SeungTae Kim, PhMD (1)